Yukihito Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yukihito Sato has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Hisayoshi Fujiwara
Department of Cardiovascular Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo, Japan
10 shared publications- Takeshi Morimoto
Department of Data Science, Hyogo Medical University, Nishinomiya 663-8501, Japan
10 shared publications Yoshiki Takatsu
Department of Cardiovascular Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo, Japan
10 shared publications- Takeshi Kimura
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
9 shared publications - Yusuke Yoshikawa
Hyogo Medical University
7 shared publications Ryoji Taniguchi
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center
6 shared publications
Latest Publications
- Open Access
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e043203
Association of Dementia With the Outcome of Patients With Heart Failure: Evidence From the Japanese KCHF Registry
Background: Patients with heart failure (HF) have a significantly higher prevalence of cognitive impairment than those without HF. While the association of dementia with prognosis of patients with HF is well documented in Western populations, data from large, prospective cohorts in East Asia, particularly Japan, remain limited. Methods: The KCHF (Kyoto Congestive Heart Failure) registry, a prospective cohort study, enrolled consecutive patients admitted for acute decompensated HF in Japan. We evaluated 3728 patients who were alive at discharge and for whom follow‐up data were available. We compared 1‐year clinical outcomes between patients with and without dementia. Results: Of 3728 participants, 658 (17.6%) were diagnosed with dementia. Patients with dementia were older, more likely to be men, more often had atrial fibrillation and prior stroke with poorer daily life activities and poor adherence to medical therapy, and less often received guideline‐directed medications at discharge than those without dementia. After adjustment for confounders, the excess risk of patients with dementia compared with those without dementia remained significant for all‐cause death and cardiovascular death (hazard ratio [HR], 1.45 [95% CI, 1.17–1.79]; P =0.0007; HR, 1.48 [95% CI, 1.12–1.95]; P =0.006, respectively). However, the excess risk of patients with dementia compared with those without dementia was no longer significant for noncardiovascular death and HF hospitalization (HR, 1.36 [95% CI, 0.96–1.91]; P =0.08; HR, 1.08 [95% CI, 0.88–1.33]; P =0.45, respectively). Conclusions: Dementia in patients with HF is associated with the risk for all‐cause death as well as cardiovascular death.
- 16 December 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e043203
Open AccessAssociation of Dementia With the Outcome of Patients With Heart Failure: Evidence From the Japanese KCHF Registry
Background: Patients with heart failure (HF) have a significantly higher prevalence of cognitive impairment than those without HF. While the association of dementia with prognosis of patients with HF is well documented in Western populations, data from large, prospective cohorts in East Asia, particularly Japan, remain limited. Methods: The KCHF (Kyoto Congestive Heart Failure) registry, a prospective cohort study, enrolled consecutive patients admitted for acute decompensated HF in Japan. We evaluated 3728 patients who were alive at discharge and for whom follow‐up data were available. We compared 1‐year clinical outcomes between patients with and without dementia. Results: Of 3728 participants, 658 (17.6%) were diagnosed with dementia. Patients with dementia were older, more likely to be men, more often had atrial fibrillation and prior stroke with poorer daily life activities and poor adherence to medical therapy, and less often received guideline‐directed medications at discharge than those without dementia. After adjustment for confounders, the excess risk of patients with dementia compared with those without dementia remained significant for all‐cause death and cardiovascular death (hazard ratio [HR], 1.45 [95% CI, 1.17–1.79]; P =0.0007; HR, 1.48 [95% CI, 1.12–1.95]; P =0.006, respectively). However, the excess risk of patients with dementia compared with those without dementia was no longer significant for noncardiovascular death and HF hospitalization (HR, 1.36 [95% CI, 0.96–1.91]; P =0.08; HR, 1.08 [95% CI, 0.88–1.33]; P =0.45, respectively). Conclusions: Dementia in patients with HF is associated with the risk for all‐cause death as well as cardiovascular death.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037652
Effectiveness of an Impella Versus Intra‐Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037652
Open AccessEffectiveness of an Impella Versus Intra‐Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation
Background: It is unclear whether an intra‐aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is better. Methods: Using the Japanese Diagnosis Procedure Combination database from September 2016 to March 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in‐hospital mortality, and the secondary outcomes included the length of hospital stay, length of ECMO, total hospitalization cost, complications, and durable mechanical circulatory support implantations. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14 319 eligible patients, 590 (4.1%) received ECPella and 13 729 (96%) received ECMO+IABP. The mean age of patients was 65 years, 77% were men, and 57% had acute coronary syndrome. After propensity score matching, the patient characteristics were well balanced between the groups. The 14‐day mortality rate was lower in the ECPella group than in the ECMO+IABP group (28.0% versus 36.8%; risk difference, −8.2% [95% CI, −13.8 to −2.7]), whereas there was no significant difference in in‐hospital mortality between the groups (58.3% versus 56.6%; risk difference, 2.4% [95% CI, −3.5 to 8.2]). The ECPella group had a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed no significant difference in in‐hospital mortality between the groups, but ECPella was associated with a higher total hospitalization cost, increased renal replacement therapy during hospitalization, and more durable mechanical circulatory support implantations than ECMO+IABP.
- Open Access
Effectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation
Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes. Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, −3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed that ECPella was not associated with a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.
Open AccessEffectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation
Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes. Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, −3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed that ECPella was not associated with a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.
- Open Access
Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT study
Background: The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a 12-month versus 3-month edoxaban treatment in terms of fewer thrombotic events for cancer-associated isolated distal deep vein thrombosis; however, concern for increased bleeding with longer anticoagulation remains. Methods: In this post-hoc analysis of the ONCO DVT study, we compared 12-month and 3-month edoxaban treatments in terms of the net adverse clinical events (NACE) as a composite endpoint of the primary endpoint (symptomatic recurrent VTE and VTE-related death at 12 months) and major secondary endpoint (major bleeding at 12-months) of the ONCO DVT study. The net clinical benefit of a 12-month over 3-month treatment was defined as the sum of the differences in the incidence of thrombotic and bleeding events between the 3-month and 12-month treatments. The weight of bleeding events was set at 1.0, and we assessed the changes in the net clinical benefit with weights of bleeding events set at 0.5 and 2.0. Results: With a weight of bleeding events of 1.0, NACE occurred in 30 of 296 patients (10.1%) in the 12-month edoxaban group and in 42 of 305 patients (13.8%) in the 3-month edoxaban group. The net clinical benefit was 3.6% (95% CI, -1.5% to 8.8%). There was a significant treatment-by-subgroup interaction between the thrombocytopenia or cancer metastasis subgroup factors and the effect of the 12-month relative to the 3-month treatment for NACE. As the weights of bleeding events changed from 0.5 to 2.0, the net clinical benefit in the 12-month edoxaban group as compared to the 3-month edoxaban group became attenuated from 4.8% (95% CI, 0.5% to 9.0%) to 0.7% (95% CI, -5.7% to 7.1%). Conclusions: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant; however, the 12-month treatment had a numerically lower incidence of NACE than the 3-month treatment. Clinical Trial Registration: ClinicalTrials.gov, NCT03895502 . Clinical Perspective: What is new?: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant in terms of the net clinical adverse events (NACE) combined with symptomatic recurrent venous thromboembolism (VTE), VTE-related death, or major bleeding with a weight of bleeding events of 1.0, however, the 12-month group had a numerically lower incidence of the NACE than the 3-month group. The net clinical benefit of the 12-month over 3-month edoxaban treatment became attenuated as the weights of the bleeding events increased. What are the clinical implications?: The present study revealed that the 12-month edoxaban treatment compared with the 3-month edoxaban treatment was basically favorable in terms of NACE; however, the net clinical benefit of the 12-month edoxaban treatment became attenuated as the weights of the bleeding events increased. Further studies should be required to evaluate the case fatality rate of each event and its impact on cancer treatment.
Open AccessNet Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis: ONCO DVT study
Background: The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a 12-month versus 3-month edoxaban treatment in terms of fewer thrombotic events for cancer-associated isolated distal deep vein thrombosis; however, concern for increased bleeding with longer anticoagulation remains. Methods: In this post-hoc analysis of the ONCO DVT study, we compared 12-month and 3-month edoxaban treatments in terms of the net adverse clinical events (NACE) as a composite endpoint of the primary endpoint (symptomatic recurrent VTE and VTE-related death at 12 months) and major secondary endpoint (major bleeding at 12-months) of the ONCO DVT study. The net clinical benefit of a 12-month over 3-month treatment was defined as the sum of the differences in the incidence of thrombotic and bleeding events between the 3-month and 12-month treatments. The weight of bleeding events was set at 1.0, and we assessed the changes in the net clinical benefit with weights of bleeding events set at 0.5 and 2.0. Results: With a weight of bleeding events of 1.0, NACE occurred in 30 of 296 patients (10.1%) in the 12-month edoxaban group and in 42 of 305 patients (13.8%) in the 3-month edoxaban group. The net clinical benefit was 3.6% (95% CI, -1.5% to 8.8%). There was a significant treatment-by-subgroup interaction between the thrombocytopenia or cancer metastasis subgroup factors and the effect of the 12-month relative to the 3-month treatment for NACE. As the weights of bleeding events changed from 0.5 to 2.0, the net clinical benefit in the 12-month edoxaban group as compared to the 3-month edoxaban group became attenuated from 4.8% (95% CI, 0.5% to 9.0%) to 0.7% (95% CI, -5.7% to 7.1%). Conclusions: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant; however, the 12-month treatment had a numerically lower incidence of NACE than the 3-month treatment. Clinical Trial Registration: ClinicalTrials.gov, NCT03895502 . Clinical Perspective: What is new?: The net clinical benefit of the 12-month over 3-month edoxaban treatment was not significant in terms of the net clinical adverse events (NACE) combined with symptomatic recurrent venous thromboembolism (VTE), VTE-related death, or major bleeding with a weight of bleeding events of 1.0, however, the 12-month group had a numerically lower incidence of the NACE than the 3-month group. The net clinical benefit of the 12-month over 3-month edoxaban treatment became attenuated as the weights of the bleeding events increased. What are the clinical implications?: The present study revealed that the 12-month edoxaban treatment compared with the 3-month edoxaban treatment was basically favorable in terms of NACE; however, the net clinical benefit of the 12-month edoxaban treatment became attenuated as the weights of the bleeding events increased. Further studies should be required to evaluate the case fatality rate of each event and its impact on cancer treatment.
- Open Access
- 25 December 2023
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (1) , 2-9
Developing Multidisciplinary Management of Heart Failure in the Super-Aging Society of Japan
The Japanese population is rapidly aging because of its long life expectancy and low birth rate; additionally, the number of patients with heart failure (HF) is increasing to the extent that HF is now considered a pandemic. According to a recent HF registry study, Japanese patients with HF have both medical and care-related problems. Although hospitalization is used to provide medical services, and institutionalization is used to provide care for frail older adults, it can be difficult to distinguish between them. In this context, multidisciplinary management of HF has become increasingly important in preventing hospital readmissions and maintaining a patient’s quality of life. Academia has promoted an increase in the number of certified HF nurses and educators. Researchers have issued numerous guidelines or statements on topics such as cardiac rehabilitation, nutrition, and palliative care, in addition to the diagnosis and treatment of acute and chronic HF. Moreover, the Japanese government has created incentives through various medical and long-term care systems adjustments to increase collaboration between these two fields. This review summarizes current epidemiological registries that focus not only on medical but also care-related problems and the 10 years of multidisciplinary management experience in Japanese medical and long-term care systems.
- 25 December 2023
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (1) , 2-9
Open AccessDeveloping Multidisciplinary Management of Heart Failure in the Super-Aging Society of Japan
The Japanese population is rapidly aging because of its long life expectancy and low birth rate; additionally, the number of patients with heart failure (HF) is increasing to the extent that HF is now considered a pandemic. According to a recent HF registry study, Japanese patients with HF have both medical and care-related problems. Although hospitalization is used to provide medical services, and institutionalization is used to provide care for frail older adults, it can be difficult to distinguish between them. In this context, multidisciplinary management of HF has become increasingly important in preventing hospital readmissions and maintaining a patient’s quality of life. Academia has promoted an increase in the number of certified HF nurses and educators. Researchers have issued numerous guidelines or statements on topics such as cardiac rehabilitation, nutrition, and palliative care, in addition to the diagnosis and treatment of acute and chronic HF. Moreover, the Japanese government has created incentives through various medical and long-term care systems adjustments to increase collaboration between these two fields. This review summarizes current epidemiological registries that focus not only on medical but also care-related problems and the 10 years of multidisciplinary management experience in Japanese medical and long-term care systems.
- 21 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (21) , 1665-1676
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary end point was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary end point was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Haemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary end point. RESULTS: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of deep vein thrombosis at baseline. The primary end point of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03–0.44). The major secondary end point of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75–2.41). The prespecified subgroups did not affect the estimates on the primary end point. CONCLUSIONS: In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03895502.
- 21 November 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (21) , 1665-1676
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned patients with cancer with isolated distal deep vein thrombosis, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary end point was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary end point was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Haemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary end point. RESULTS: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of deep vein thrombosis at baseline. The primary end point of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03–0.44). The major secondary end point of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 patients (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75–2.41). The prespecified subgroups did not affect the estimates on the primary end point. CONCLUSIONS: In patients with cancer with isolated distal deep vein thrombosis, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03895502.
- Open Access
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0287637
Weight loss during follow-up in patients with acute heart failure: From the KCHF registry
Backgrounds: The prognostic implication of weight loss after discharge from acute heart failure (AHF) remains unclear. We sought to investigate the association of weight loss between discharge and 6-month visit with subsequent clinical outcomes in patients with AHF. Methods: We analyzed 686 patients with AHF in the prospective longitudinal follow-up study derived from the Kyoto Congestive Heart Failure registry, and divided them into 2 groups based on the weight loss at 6-month index visit. We defined the weight loss as ≥ 5% decrease in body weight from discharge to 6-month index visit. Results: There were 90 patients (13.1%) with a weight loss at 6-month visit. Patients in the weight loss group compared with those in the no weight loss group had higher body weight at discharge and lower body weight at 6-mont visit. Patients in the weight loss group had a lower systolic blood pressure, higher brain-type natriuretic peptide, lower serum albumin, lower hemoglobin, higher prevalence of heart failure with reduced ejection fraction at 6-month visit, and a lower prescription rate of inhibitors of renin-angiotensin system than those in the no weight loss group. The cumulative 6-month incidence of all-cause death was significantly higher in the weight loss group than in the no weight loss group (14.2% and 4.3%, log-rank P<0.001). The excess adjusted risk of the weight loss group relative to the no weight loss group remained significant for all-cause death (HR 2.39, 95%CI 1.01–5.65, P = 0.048). Conclusion: Body weight loss of ≥5% at 6-month visit after discharge was associated with subsequent all-cause death in patients with AHF.
- 23 June 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (6) , e0287637
Open AccessWeight loss during follow-up in patients with acute heart failure: From the KCHF registry
Backgrounds: The prognostic implication of weight loss after discharge from acute heart failure (AHF) remains unclear. We sought to investigate the association of weight loss between discharge and 6-month visit with subsequent clinical outcomes in patients with AHF. Methods: We analyzed 686 patients with AHF in the prospective longitudinal follow-up study derived from the Kyoto Congestive Heart Failure registry, and divided them into 2 groups based on the weight loss at 6-month index visit. We defined the weight loss as ≥ 5% decrease in body weight from discharge to 6-month index visit. Results: There were 90 patients (13.1%) with a weight loss at 6-month visit. Patients in the weight loss group compared with those in the no weight loss group had higher body weight at discharge and lower body weight at 6-mont visit. Patients in the weight loss group had a lower systolic blood pressure, higher brain-type natriuretic peptide, lower serum albumin, lower hemoglobin, higher prevalence of heart failure with reduced ejection fraction at 6-month visit, and a lower prescription rate of inhibitors of renin-angiotensin system than those in the no weight loss group. The cumulative 6-month incidence of all-cause death was significantly higher in the weight loss group than in the no weight loss group (14.2% and 4.3%, log-rank P<0.001). The excess adjusted risk of the weight loss group relative to the no weight loss group remained significant for all-cause death (HR 2.39, 95%CI 1.01–5.65, P = 0.048). Conclusion: Body weight loss of ≥5% at 6-month visit after discharge was associated with subsequent all-cause death in patients with AHF.
- Open Access
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e028981
Trends in Treatment Patterns and Outcomes of Patients With Pulmonary Embolism in Japan, 2010 to 2020: A Nationwide Inpatient Database Study
Background: The impact of major changes in the treatment practice of pulmonary embolism (PE), such as limited indications for systemic thrombolysis and the introduction of direct oral anticoagulants, is not well documented. This study aimed to describe annual trends in the treatment patterns and outcomes in patients with PE. Methods and Results: Using the Japanese Diagnosis Procedure Combination inpatient database from April 2010 to March 2021, we identified hospitalized patients with PE. Patients with high‐risk PE were defined as those admitted for out‐of‐hospital cardiac arrest or who received cardiopulmonary resuscitation, extracorporeal membrane oxygenation, vasopressors, or invasive mechanical ventilation on the day of admission. The remaining patients were defined as patients with non–high‐risk PE. The patient characteristics and outcomes were reported with fiscal year trend analyses. Of 88 966 eligible patients, 8116 (9.1%) had high‐risk PE, and the remaining 80 850 (90.9%) had non–high‐risk PE. Between 2010 and 2020, in patients with high‐risk PE, the annual proportion of extracorporeal membrane oxygenation use significantly increased from 11.0% to 21.3%, whereas that of thrombolysis use significantly decreased from 22.5% to 15.5% ( P for trend P for trend=0.04). In patients with non–high‐risk PE, the annual proportion of direct oral anticoagulant use increased from 0.0% to 38.3%, whereas that of thrombolysis use significantly decreased from 13.7% to 3.4% ( P for trend P for trend <0.001). Conclusions: Substantial changes in the PE practice and outcomes occurred in patients with high‐risk and non–high‐risk PE.
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e028981
Open AccessTrends in Treatment Patterns and Outcomes of Patients With Pulmonary Embolism in Japan, 2010 to 2020: A Nationwide Inpatient Database Study
Background: The impact of major changes in the treatment practice of pulmonary embolism (PE), such as limited indications for systemic thrombolysis and the introduction of direct oral anticoagulants, is not well documented. This study aimed to describe annual trends in the treatment patterns and outcomes in patients with PE. Methods and Results: Using the Japanese Diagnosis Procedure Combination inpatient database from April 2010 to March 2021, we identified hospitalized patients with PE. Patients with high‐risk PE were defined as those admitted for out‐of‐hospital cardiac arrest or who received cardiopulmonary resuscitation, extracorporeal membrane oxygenation, vasopressors, or invasive mechanical ventilation on the day of admission. The remaining patients were defined as patients with non–high‐risk PE. The patient characteristics and outcomes were reported with fiscal year trend analyses. Of 88 966 eligible patients, 8116 (9.1%) had high‐risk PE, and the remaining 80 850 (90.9%) had non–high‐risk PE. Between 2010 and 2020, in patients with high‐risk PE, the annual proportion of extracorporeal membrane oxygenation use significantly increased from 11.0% to 21.3%, whereas that of thrombolysis use significantly decreased from 22.5% to 15.5% ( P for trend P for trend=0.04). In patients with non–high‐risk PE, the annual proportion of direct oral anticoagulant use increased from 0.0% to 38.3%, whereas that of thrombolysis use significantly decreased from 13.7% to 3.4% ( P for trend P for trend <0.001). Conclusions: Substantial changes in the PE practice and outcomes occurred in patients with high‐risk and non–high‐risk PE.
- 13 August 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 181, 9-17
Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention
- 13 August 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 181, 9-17
Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention
- Open Access
- 5 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0267327
Appetite loss at discharge from acute decompensated heart failure: Observation from KCHF registry
Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.
- 5 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0267327
Open AccessAppetite loss at discharge from acute decompensated heart failure: Observation from KCHF registry
Objective: The complex link between nutritional status, protein and lipid synthesis, and immunity plays an important prognostic role in patients with heart failure. However, the association between appetite loss at discharge and long-term outcome remains unclear. Methods: The Kyoto Congestive Heart Failure registry is a prospective cohort study that enrolled consecutive patients hospitalized for acute decompensated heart failure (ADHF) in Japan. We assessed 3528 patients alive at discharge, and for whom appetite and follow-up data were available. We compared one-year clinical outcomes in patients with and without appetite loss at discharge. Results: In the multivariable logistic regression analysis using 19 clinical and laboratory factors with P value < 0.1 by univariate analysis, BMI < 22 kg/m2 (odds ratio (OR): 1.57, 95% confidence interval (CI): 1.11–2.24, P = 0.01), CRP >1.0mg/dL (OR: 1.49, 95%CI: 1.04–2.14, P = 0.03), and presence of edema at discharge (OR: 4.30, 95%CI: 2.99–6.22, P<0.001) were associated with an increased risk of appetite loss at discharge, whereas ambulatory status (OR: 0.57, 95%CI: 0.39–0.83, P = 0.004) and the use of ACE-I/ARB (OR: 0.70, 95% CI: 0.50–0.98, P = 0.04) were related to a decreased risk in the presence of appetite loss. The cumulative 1-year incidence of all-cause death (primary outcome measure) was significantly higher in patients with appetite loss than in those without appetite loss (31.0% vs. 15.0%, P<0.001). The excess adjusted risk of appetite loss relative to no appetite loss remained significant for all-cause death (hazard ratio (HR): 1.63, 95%CI: 1.29–2.07, P<0.001). Conclusions: Loss of appetite at discharge was associated with worse 1-year mortality in patients with ADHF. Appetite is a simple, reliable, and useful subjective marker for risk stratification of patients with ADHF.